| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 853 | 2022 |
| Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features J Calderaro, B Rousseau, G Amaddeo, M Mercey, C Charpy, C Costentin, ... Hepatology 64 (6), 2038-2046, 2016 | 425 | 2016 |
| Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma J Calderaro, F Petitprez, E Becht, A Laurent, TZ Hirsch, B Rousseau, ... Journal of hepatology 70 (1), 58-65, 2019 | 274 | 2019 |
| Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction T Simon, S Taleb, N Danchin, L Laurans, B Rousseau, S Cattan, ... European heart journal 34 (8), 570-577, 2013 | 209 | 2013 |
| DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity C Lu, J Guan, S Lu, Q Jin, B Rousseau, T Lu, D Stephens, H Zhang, J Zhu, ... Cancer cell 39 (1), 96-108. e6, 2021 | 185 | 2021 |
| The spectrum of benefit from checkpoint blockade in hypermutated tumors B Rousseau, MB Foote, SB Maron, BH Diplas, S Lu, G Argilés, A Cercek, ... New England Journal of Medicine 384 (12), 1168-1170, 2021 | 168 | 2021 |
| PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma J Fontugne, J Augustin, A Pujals, P Compagnon, B Rousseau, A Luciani, ... Oncotarget 8 (15), 24644, 2017 | 165 | 2017 |
| Pharmacologic modulation of RNA splicing enhances anti-tumor immunity SX Lu, E De Neef, JD Thomas, E Sabio, B Rousseau, M Gigoux, DA Knorr, ... Cell 184 (15), 4032-4047. e31, 2021 | 162 | 2021 |
| Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions M Hilmi, C Neuzillet, J Calderaro, F Lafdil, JM Pawlotsky, B Rousseau Journal for immunotherapy of cancer 7, 1-13, 2019 | 138 | 2019 |
| KRAS oncogene in lung cancer: focus on molecularly driven clinical trials E Kempf, B Rousseau, B Besse, L Paz-Ares European respiratory review 25 (139), 71-76, 2016 | 110 | 2016 |
| Sorafenib exposure decreases over time in patients with hepatocellular carcinoma J Arrondeau, O Mir, P Boudou-Rouquette, R Coriat, S Ropert, G Dumas, ... Investigational new drugs 30, 2046-2049, 2012 | 107 | 2012 |
| Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR) JM Phelip, D Tougeron, D Léonard, L Benhaim, G Desolneux, A Dupré, ... Digestive and Liver Disease 51 (10), 1357-1363, 2019 | 105 | 2019 |
| Alternative Neisseria spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue J Chamot-Rooke, B Rousseau, F Lanternier, G Mikaty, E Mairey, ... Proceedings of the National Academy of Sciences 104 (37), 14783-14788, 2007 | 97 | 2007 |
| Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study B Rousseau, P Loulergue, O Mir, A Krivine, S Kotti, E Viel, T Simon, ... Annals of oncology 23 (2), 450-457, 2012 | 90 | 2012 |
| Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond R Cohen, B Rousseau, J Vidal, R Colle, LA Diaz, T André Targeted oncology 15, 11-24, 2020 | 85 | 2020 |
| Polymerase proofreading domain mutations: new opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency R Bourdais, B Rousseau, A Pujals, H Boussion, C Joly, A Guillemin, ... Critical Reviews in Oncology/Hematology 113, 242-248, 2017 | 79 | 2017 |
| FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts C Neuzillet, O Hentic, B Rousseau, V Rebours, L Bengrine-Lefèvre, ... World journal of gastroenterology: WJG 18 (33), 4533, 2012 | 63 | 2012 |
| Stage II and stage III colon cancer: treatment advances and future directions B Rousseau, B Chibaudel, JB Bachet, AK Larsen, C Tournigand, ... The Cancer Journal 16 (3), 202-209, 2010 | 51 | 2010 |
| CD4 T cell–dependent rejection of beta-2 microglobulin null mismatch repair–deficient tumors G Germano, S Lu, G Rospo, S Lamba, B Rousseau, S Fanelli, D Stenech, ... Cancer discovery 11 (7), 1844-1859, 2021 | 47 | 2021 |
| Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC–MS/MS M Allard, N Khoudour, B Rousseau, C Joly, C Costentin, B Blanchet, ... Journal of pharmaceutical and biomedical analysis 142, 42-48, 2017 | 45 | 2017 |
Thierry AndréHôpital Saint Antoine在 aphp.fr 的电子邮件经过验证
